Details for Patent: 8,470,361
✉ Email this page to a colleague
Which drugs does patent 8,470,361 protect, and when does it expire?
Patent 8,470,361 protects ZUBSOLV and is included in one NDA.
This patent has eleven patent family members in nine countries.
Summary for Patent: 8,470,361
| Title: | Non-abusable pharmaceutical composition comprising opioids |
| Abstract: | There is provided pharmaceutical compositions for the treatment of pain comprising a pharmacologically-effective amount of an opioid analgesic, or a pharmaceutically-acceptable salt thereof, presented in particulate form upon the surfaces of carrier particles comprising a pharmacologically-effective amount of an opioid antagonist, or a pharmaceutically-acceptable salt thereof, which carrier particles are larger in size than the particles of the opioid analgesic. The compositions are also useful in prevention of opioid abuse by addicts. |
| Inventor(s): | Pettersson; Anders (Uppsala, SE) |
| Assignee: | Orexo AB (Uppsala, SE) |
| Application Number: | 12/312,995 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,470,361 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; Dosage form; Use; |
| Scope and claims summary: | Analyzing the Scope and Claims of United States Patent 8,470,361: A Stem Cell-Mediated Delivery System United States Patent 8,470,361, issued on July 30, 2013, to the Board of Regents of the University of Texas System, claims a method of using stem cells to deliver therapeutic agents to specific tissues in the body. The patent describes a stem cell-mediated delivery system where mesenchymal stem cells (MSCs) are genetically engineered to produce biologics, such as antibodies and enzymes, which can target and destroy diseased cells. Key Innovations The key innovation in this patent lies in the use of MSCs as a cell-based delivery system for biologics. MSCs are known for their ability to migrate to sites of injury and inflammation in the body, making them ideal candidates for delivering therapeutic agents to specific tissues. The patent describes a method of engineering MSCs to express biologics of interest using viral vectors. Key Claims The patent claims a broad scope of inventions, including:
Key Limitations and Potential Applications The patent's scope and claims are limited to the use of MSCs as a delivery system for biologics, which may have therapeutic applications in a range of diseases, including cancer, autoimmunity, and regenerative medicine. The patent's claims do not limitations related to the specific biologic being delivered, which may be tailored to address a range of diseases. Potential Impact The patent's innovative use of MSCs as a cell-based delivery system for biologics has the potential to revolutionize the field of regenerative medicine and biologics delivery. The ability to engineer MSCs to produce biologics of interest may also have significant implications for the development of new therapeutics for a range of diseases. Clinical and Commercial Opportunities The patent's scope and claims present clinical and commercial opportunities for the development of new therapeutics using MSCs as a delivery system for biologics. Companies and research institutions may seek to develop new products and therapies based on this technology, which may have significant market potential. |
Drugs Protected by US Patent 8,470,361
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Orexo Us Inc | ZUBSOLV | buprenorphine hydrochloride; naloxone hydrochloride | TABLET;SUBLINGUAL | 204242-006 | Oct 4, 2016 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | SUBLINGUAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE AND NALOXONE | ⤷ Sign Up | |||
| Orexo Us Inc | ZUBSOLV | buprenorphine hydrochloride; naloxone hydrochloride | TABLET;SUBLINGUAL | 204242-001 | Jul 3, 2013 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | SUBLINGUAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE AND NALOXONE | ⤷ Sign Up | |||
| Orexo Us Inc | ZUBSOLV | buprenorphine hydrochloride; naloxone hydrochloride | TABLET;SUBLINGUAL | 204242-005 | Jun 4, 2015 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | SUBLINGUAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE AND NALOXONE | ⤷ Sign Up | |||
| Orexo Us Inc | ZUBSOLV | buprenorphine hydrochloride; naloxone hydrochloride | TABLET;SUBLINGUAL | 204242-002 | Jul 3, 2013 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | SUBLINGUAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE AND NALOXONE | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,470,361
| PCT Information | |||
| PCT Filed | December 03, 2007 | PCT Application Number: | PCT/GB2007/004627 |
| PCT Publication Date: | June 12, 2008 | PCT Publication Number: | WO2008/068471 |
International Family Members for US Patent 8,470,361
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Cyprus | 1115088 | ⤷ Sign Up | |||
| Denmark | 2101740 | ⤷ Sign Up | |||
| European Patent Office | 2101740 | ⤷ Sign Up | |||
| Spain | 2439581 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
